News and Events

LD Micro 12th Annual Main Event

Disclosure and Forward Looking Statement — This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current views and assumptions, speak only as of the date hereof and are subject to … Continued

ThermoGenesis Holdings Updates 510(K) Listing with the FDA to Include its Next Generation PXP®-1000 System for Advanced Cellular Processing

RANCHO CORDOVA, Calif., Dec. 10, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has completed the development process and submitted a Letter to the Design History File and updated the device listing with the U.S. Food … Continued

ThermoGenesis Holdings to Present at the LD Micro 12th Annual Main Event

RANCHO CORDOVA, Calif., Dec. 5, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced Chris Xu, Ph.D., Chairman and Chief Executive Officer, will present a company overview at the LD Micro 12th Annual Main Event at the Luxe Sunset … Continued

ThermoGenesis Holdings Closes Joint Venture Agreement With HealthBanks Biotech (USA) to Form ImmuneCyte Life Sciences

ImmuneCyte to Begin Operations by Year End 2019   RANCHO CORDOVA, Calif., Nov. 26, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the company has closed on its joint venture agreement with HealthBanks Biotech (USA) Inc., a … Continued

Corporate Presentation

Disclosure and Forward Looking Statement — This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current views and assumptions, speak only as of the date hereof and are subject to … Continued

ThermoGenesis Holdings Announces Improved Third Quarter 2019 Financial Results and Provides Corporate Update

Reports Second Consecutive Quarter of Positive Cash Flow; Recent Name Change Aligns with Shift in Strategic Focus   Conference Call to be Held Today at 1:30 p.m. PST/4:30 p.m. EST   RANCHO CORDOVA, Calif., November 19, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and … Continued

ThermoGenesis Holdings to Postpone Third Quarter 2019 Earnings Release and Conference Call Until Tuesday November 19, 2019

RANCHO CORDOVA, Calif., Nov. 14, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced it will delay its third quarter ended September 30, 2019 earnings release and subsequent earnings conference call, previously scheduled for … Continued

ThermoGenesis Holdings to Delay Third Quarter 2019 Earnings Release and Conference Call Until Thursday November 14, 2019

RANCHO CORDOVA, Calif., Nov. 12, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced  it will delay its third quarter ended September 30, 2019 earnings release and conference call, previously scheduled for today, … Continued

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2019 and Provide a Corporate Strategic Update

Conference Call to be Held on November 12, 2019 RANCHO CORDOVA, Calif., Nov. 6, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing for regenerative medicine, today announced that the Company will release its financial results for the third quarter ended September 30, 2019 and provide a strategic corporate update on Tuesday, … Continued

Cesca Therapeutics to Change Name and Ticker Symbol to Reflect New Strategic Focus

ThermoGenesis to Focus on Developing Automated Cell Processing Tools and Services for the Cell and Gene Therapy Field RANCHO CORDOVA, Calif., Oct. 31, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing for regenerative medicine, today announced that the company will change its name to ThermoGenesis Holdings, Inc. (“ThermoGenesis”) in … Continued

© 2019 ThermoGenesis Corp.
How may we help?